190 related articles for article (PubMed ID: 37342587)
1. Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia.
Ong SC; Low JZ; Linden S
Front Pharmacol; 2023; 14():1195124. PubMed ID: 37342587
[No Abstract] [Full Text] [Related]
2. Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.
Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Idehara K; Nitta D
ESC Heart Fail; 2024 Feb; 11(1):261-270. PubMed ID: 37969049
[TBL] [Abstract][Full Text] [Related]
3. Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40.
Kolovos S; Bellanca L; Groyer H; Rosano GMC; Solé A; Gaultney J; Linden S
ESC Heart Fail; 2023 Dec; 10(6):3385-3397. PubMed ID: 37670496
[TBL] [Abstract][Full Text] [Related]
4. Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE
Fauchier L; Lamblin N; Tardu J; Bellier L; Groyer H; Ittah D; Chollet J; Linden S; Levy P
Pharmacoecon Open; 2024 Jan; 8(1):19-30. PubMed ID: 37606866
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective.
Lin X; Lin M; Liu M; Huang W; Nie X; Chen Z; Zheng B
J Thorac Dis; 2022 May; 14(5):1588-1597. PubMed ID: 35693603
[TBL] [Abstract][Full Text] [Related]
6. A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction.
Tafazzoli A; Reifsnider OS; Bellanca L; Ishak J; Carrasco M; Rakonczai P; Stargardter M; Linden S
Eur J Health Econ; 2023 Dec; 24(9):1441-1454. PubMed ID: 36463524
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China.
Tang Y; Sang H
Front Pharmacol; 2022; 13():1030642. PubMed ID: 36386229
[No Abstract] [Full Text] [Related]
8. Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China.
Jiang Y; Zheng R; Sang H
Front Pharmacol; 2021; 12():733681. PubMed ID: 34858172
[No Abstract] [Full Text] [Related]
9. Cost-Effectiveness of Empagliflozin on Top of Standard of Care for Heart Failure With Reduced Ejection Fraction in Singapore.
Varghese L; Lin W; Linden S; Lum AL; Sim D
Value Health Reg Issues; 2023 Mar; 34():108-117. PubMed ID: 36669346
[TBL] [Abstract][Full Text] [Related]
10. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial.
Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Reifsnider OS; Rakonczai P; Stargardter M; Murata T; Hirase T; Nitta D
J Cardiol; 2023 Jun; 81(6):522-530. PubMed ID: 36858174
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region.
Liao CT; Yang CT; Kuo FH; Lee MC; Chang WT; Tang HJ; Hua YM; Chang HY; Chen ZC; Strong C; Ou HT; Toh HS
Front Cardiovasc Med; 2021; 8():750381. PubMed ID: 34778407
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction.
Nguyen BN; Mital S; Bugden S; Nguyen HV
Int J Cardiol; 2023 Apr; 376():83-89. PubMed ID: 36736672
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland.
Hallinen T; Kivelä S; Soini E; Harjola VP; Pesonen M
Clinicoecon Outcomes Res; 2023; 15():1-13. PubMed ID: 36636485
[TBL] [Abstract][Full Text] [Related]
15. Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
Krittayaphong R; Permsuwan U
Am J Cardiovasc Drugs; 2022 Sep; 22(5):577-590. PubMed ID: 35796952
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China.
Jiang Y; Xie J
Front Cardiovasc Med; 2022; 9():946399. PubMed ID: 36119747
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.
Zheng J; Parizo JT; Spertus JA; Heidenreich PA; Sandhu AT
JAMA Intern Med; 2022 Dec; 182(12):1278-1288. PubMed ID: 36342696
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States.
Nechi RN; Rane A; Karaye RM; Ndikumukiza C; Alsahali S; Jatau AI; Zoni CR; Alanzi A; Karaye IM; Yunusa I
Clin Ther; 2023 Jul; 45(7):627-632. PubMed ID: 37270374
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China.
Sang H; Wan Y; Ma Z; Zhang S; Zhao Q
Front Cardiovasc Med; 2022; 9():1022020. PubMed ID: 36465457
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States.
Reifsnider OS; Tafazzoli A; Linden S; Ishak J; Rakonczai P; Stargardter M; Kuti E
J Am Heart Assoc; 2024 Feb; 13(4):e029042. PubMed ID: 38362909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
